HER-2/neu gene amplification status in prostate cancer by fluorescence in situ hybridization

Human Pathology

Volumn 28, Issue 7, 1997, Pages 827-833

  Ross, Jeffrey S ^a   Sheehan, Christine ^b   Hayner Buchan, Alida M ^b   Ambros, Robert A ^b   Kallakury, Bhaskar V S ^b   Kaufman, Ronald ^b   Fisher, Hugh A G ^b   Muraca, Patrick J ^b  

^a ALBANY MEDICAL COLLEGE   (United States)

^b NONE

Author keywords

Fluorescence in situ hybridization; HER 2 neu; Prostate carcinoma

Indexed keywords

DIGOXIGENIN; DNA; FORMALDEHYDE; PARAFFIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER STAGING; CONTROLLED STUDY; DNA CONTENT; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; ONCOGENE NEU; PLOIDY; PROGNOSIS; PROSTATE CANCER; TREATMENT PLANNING;

EID: 0030877481     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0046-8177(97)90157-X     Document Type: Article

References (43)

1. Boring CC, Squires TS, Tong T: Cancer Statistics 1991. CA 41:19-36, 1991
2. Lu-yao GL, Greenberg ER: Changes in prostate cancer incidence and treatment in USA. Lancet 343:251-254, 1994
3. Epstein JI, Walsh PC, Carmichael M, et al: Pathologic and clinical findings to predict tumor extent of non-palpable (Stage A-1c) prostate cancer. JAMA 271:368-374, 1994
4. Goldfinger SE (ed) : Prostate cancer: Watchful waiting. Harvard Health Letter 19:1-3, 1994
5. Chodak DW, Thisted RE, Gerber GS, et al: Results of conservative management of clinically localized prostate cancer. N Engl J Med 330:242-248, 1994
6. Berger MS, Locher GW, Saurer S, et al: Correlation of c-erbB-Z gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. Cancer Res 48:1238-1243, 1988
7. Battifora H, Gaffey M, Esteban J, et al: Immunohistochemical assay of neu/c-erbB-2 oncogene product in paraffin-embedded tissues in early breast cancer: Retrospective follow-up study of 245 stage I and II cases. Mod Pathol 4:466-474, 1991
8. Press MF, Pike MC, Chazin VR, et al: Her-2/neu expression in node-negative breast cancer: Direct tissue quantification by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res 53:4960-4970, 1993
9. Seshadri R, Firgaira FA, Horsfall DJ, et al: Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. J Clin Oncol 11:1936-1942, 1993
10. Descotes F, PavyJ-J, Adessi GL: Human breast cancer: Correlation study between HER-2/neu amplification and prognostic factors in an unselected population. Anticancer Res 13:119-124, 1993
11. Muss HB, Thor AD, Berry DA, et al: c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 330:1260-1266, 1994
12. Tetu B, Brisson J: Prognostic significance of HER-2/neu oncogene expression in node-positive breast cancer: The influence of the pattern of immunostaining and adjuvant therapy. Cancer 73:2359-2365, 1994
13. Marks JR, Humphrey PA, Wu K, et al: Overexpression of p53 and HER-2/neu proteins as prognostic markers in early stage breast cancer. Ann Surg 219:332-341, 1994
14. Visakorpi T, Kallioniemi O-P, Koivula T, et al: Expression of epidermal growth factor receptor and c-erbB-2 (HER-2/neu) oncoprotein in prostatic carcinomas. Mod Pathol 5:643-648, 1992
15. Ibriham GK, MacDonald JA, Kerns BJ, et al: Differential immunoreactivity of HER-2/neu oncoprotein in prostatic tissues. Surg Oncol 1:151-155, 1992
16. Ross JS, Nazeer T, Church K, et al: Contribution of HER-2/ neu oncogene expression to tumor grade and DNA content analysis in the prediction of prostatic carcinoma and metastasis. Cancer 72:3020-3028, 1993
17. Sadasivan R, Morgan R, Jennings S, et al: Overexpression of HER-2/neu may be an indicator of poor prognosis in prostate cancer. J Urol 150:126-131, 1993
18. Kuhn EJ, Kurnot RA, Sesterhenn IA, et al: Expression of the c-erbB-2 (HER-2/neu) oncoprotein in human prostatic carcinoma. J Urol 150:1427-1433, 1993
19. Latil A, Baron JC, Cussenot O, et al: Oncogene amplifications in early-stage human prostate carcinomas. Int J Cancer 59:637-638, 1994
20. Fournier G, Latil A, Amet Y, et al: Gene amplifications in advanced stage human prostate cancer. Urol Res 22:343-347, 1995
21. Ware JL, Maygarden SJ, Koontz WW, et al: Immunohistochemical detection of CerbB2 protein in human benign and neoplastic prostate. HUM PATHOL 22:254-258, 1991
22. Press MF, Hung G, Godolphin W, et al: Sensitivity of HER-2 antibodies in archival tissue samples: Potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 54:2771-2777, 1994
23. Press MF, Bernstein L, Thomas PA, et al: HER-2/neu (C-erbB-2) gene amplification characterized by fluorescence in situ hybridization: Poor prognosis in node-negative breast carcinomas. J Clin Oncol (in press), 1997
24. Visakorpi T, Hyytinen B, Kallioniemi A, et al: Sensitive detection of chromosome copy number aberrations in prostate cancer by fluorescence in-situ hybridization. Am J Pathol 145:624-630, 1994
25. Brown JA, Alcaraz A, Takahashi S, et al: Chromosomal aneusomies detected by fluorescent in-situ hybridization analysis in clinically localized prostate carcinoma. J Urol 152:1157-1162, 1994
26. Persons DL, Gibney DJ, Katzmann JA, et al: Use of fluorescent in-situ hybridization for deoxyribonucleic acid ploidy analysis of prostatic adenocarcinoma. J Urol 150:20-25, 1993
27. Lifson B, Pizzolo JG, El Hosseiny AA, et al: Comparison of fluorescence in-situ hybridization and flow cytometric DNA ploidy analysis in paraffin-embedded prostatic adenocarcinoma specimens. Anal Quant Cytol Histol 17:93-99, 1995
28. Koivisto P, Hyytinen E, Palmberg C, et al: Analysis of genetic changes underlying local recurrence of prostate carcinoma during androgen depravation therapy. Am J Pathol 147:1608-1614, 1995
29. Lieber MM: DNA ploidy in prostate cancer: Potential measurement as a surrogate end point biomarker. J Cell Biochem 19:246-248, 1994 (suppl)
30. Bandyk MG, Zhao L, Troncoso P, et al: Trisomy 7: A potential cytogenetic marker of human prostate cancer progression. Genes Chromosomes Cancer 9:19-27, 1994
31. Zitzelsberger H, Szucs S, Weier HU, et al: Numerical abnormalities of chromosome 7 in human prostate cancer detected by fluorescence in-situ hybridization (FISH) on paraffin-embedded tissue sections with centromere-specific DNA probes. J Pathol 172:325-335, 1994
32. Alcaraz A, Takahashi S, Brown JA, et al: Aneuploidy and aneusomy of chromosome 7 detected by fluorescence in-situ hybridization are markers of poor prognosis in prostate cancer. Cancer Res 54:3998-4002, 1994
33. Ziao S, Renshaw A, Cibas ES, et al: Novel fluorescence insitu hybridization approaches in solid tumors: Characterization of frozen specimens, touch preparations, and cytological preparations. Am J Pathol 147:896-904, 1995
34. Cher ML, Ito T, Weidner N, et al: Mapping of regions of physical deletion on chromosome 16q in prostate cancer cells by fluorescence in-situ hybridization (FISH). J Urol 153:249-254, 1995
35. Micale MA, Sanford JS, Pawell IJ, et al: Defining the extent and nature of cytogenetic events in prostatic adenocarcinoma: Paraffin FISH vs. metaphase analysis. Cancer Genet Cytogenet 69:7-12, 1993
36. Qian J, Jenkins RB, Bostwick DG: Chromosomal anomalies in atypical adenomatous hyperplasia and carcinoma of the prostate using fluorescence in-situ hybridization. Urology 46:837-842, 1995
37. Jones E, Zhu XL, Rohr LR, et al: Aneusomy of chromosomes 7 and 17 detected by FISH in prostate cancer and the effects of selection in vitro. Genes Chromosomes Cancer 11:163-170, 1994
38. Brothman AR, Watson MJ, Zhu XL, et al: Evaluation of 20 archival prostate tumor specimens by fluorescence in-situ hybridization (FISH). Cancer Genet Cytogenet 75:40-44, 1994
39. Takahashi S, Quian J, Brown JA, et al: Potential markers of prostate cancer aggressiveness detected by fluorescence in-situ hybridization in needle biopsies. Cancer Res 54:3574-3579, 1994
40. Qian J, Bostwick DG, Takahashi S, et al: Chromosomal anomalies in prostatic intraepithelial neoplasia and carcinoma detected by fluorescence in-situ hybridization. Cancer Res 55:5408-5414, 1995
41. Poller DN, Silverstein MJ, Galea M, et al: Ductal carcinoma in-situ of the breast: A proposal for a new simplified histological classification association between cellular proliferation and c-erbB-2 protein expression. Mod Pathol 7:257-262, 1994
42. Chen LL, Clawson ML, Bilgrami S, et al: A sequence-specific single-stranded DNA-binding protein that is responsive to epidermal growth factor recognizes an S1 nuclease-sensitive region in the epidermal growth factor receptor promoter. J Cell Growth Differ 4:975-983, 1993
43. Yamanaka Y, Friess H, Kobrin MS, et al: Overexpression of HER-2/neu oncogene in human pancreatic carcinoma. HUM PATHOL 24:1127-1134, 1993